Yu Dong

1.5k total citations · 2 hit papers
68 papers, 913 citations indexed

About

Yu Dong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yu Dong has authored 68 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Yu Dong's work include Lung Cancer Research Studies (12 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Yu Dong is often cited by papers focused on Lung Cancer Research Studies (12 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Yu Dong collaborates with scholars based in China, Canada and United States. Yu Dong's co-authors include Baohui Han, Yanwei Zhang, Hua Zhong, Tianqing Chu, Chunlei Shi, Xueyan Zhang, Bo Jin, Wei Nie, Yiming Zhao and Runbo Zhong and has published in prestigious journals such as SHILAP Revista de lepidopterología, Immunity and PLoS ONE.

In The Last Decade

Yu Dong

62 papers receiving 907 citations

Hit Papers

Phase 1b Study of Sintilimab Plus Anlotinib as First-line... 2021 2026 2022 2024 2021 2024 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
    2021 174 citations Tianqing Chu, Runbo Zhong et al. Journal of Thoracic Oncology profile →
  2. Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells
    2024 64 citations Rui Ding, Zhilin Hu et al. Immunity profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yu Dong China 14 455 389 213 150 106 68 913
Lin Zhao China 19 364 0.8× 308 0.8× 179 0.8× 126 0.8× 90 0.8× 62 880
Yongfeng Ding China 18 409 0.9× 213 0.5× 305 1.4× 150 1.0× 231 2.2× 51 944
Ling Guo China 16 451 1.0× 256 0.7× 330 1.5× 224 1.5× 71 0.7× 48 1.1k
Kazuhiko Yoshimatsu Japan 17 554 1.2× 298 0.8× 218 1.0× 144 1.0× 71 0.7× 184 1.2k
Itaru Omoto Japan 15 338 0.7× 264 0.7× 222 1.0× 161 1.1× 79 0.7× 48 810
Shinobu Kunugi Japan 14 188 0.4× 312 0.8× 186 0.9× 65 0.4× 74 0.7× 74 774
Donglin Sun China 19 266 0.6× 250 0.6× 283 1.3× 117 0.8× 105 1.0× 54 1.0k

Countries citing papers authored by Yu Dong

Since Specialization
Citations

This map shows the geographic impact of Yu Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Dong more than expected).

Fields of papers citing papers by Yu Dong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Dong. The network helps show where Yu Dong may publish in the future.

Co-authorship network of co-authors of Yu Dong

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Dong. A scholar is included among the top collaborators of Yu Dong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Dong. Yu Dong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xia, Zhinan, Yu Dong, Xinyu Hao, et al.. (2025). The positive feedback loop between SP1 and MAP2K2 significantly drives resistance to VEGFR inhibitors in clear cell renal cell carcinoma. International Journal of Biological Sciences. 21(2). 860–873. 3 indexed citations
2.
Tang, Jiaxiang, Yu Dong, Fangzhou Hong, et al.. (2025). 3DTopia-XL: Scaling High-quality 3D Asset Generation via Primitive Diffusion. 26576–26586. 1 indexed citations
3.
Zhang, Lijing, Pingping Liu, Hongyu Yan, et al.. (2025). Reshaping metal composition and sources to reduce PM2.5 oxidative potential by clean energy policies in Xi'an, China. Atmospheric Environment. 367. 121742–121742.
4.
Han, Yifan, Jiani Li, Yuhan Huang, et al.. (2025). Topical delivery of cultivated limbal stem cells via porous photocurable hydrogel: A noninvasive, convenient, and efficient stem cells delivery strategy for limbal stem cell deficiency. Journal of Controlled Release. 384. 113900–113900. 1 indexed citations
5.
6.
7.
Chen, Hui, Qinmei Wang, Yu Dong, et al.. (2024). Early GnRH-agonist therapy does not negatively impact the endometrial repair process or live birth rate. Frontiers in Endocrinology. 15. 1343176–1343176. 1 indexed citations
8.
Chen, Zhihui, et al.. (2024). Production efficiency analysis based on the RFID-collected manufacturing big data. Manufacturing Letters. 41. 81–90. 1 indexed citations
9.
Wang, Anqi, Yuanwei Li, Tianyou Zhang, et al.. (2024). Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors. SHILAP Revista de lepidopterología. 4(3). 280–287. 5 indexed citations
10.
Ding, Rui, Zhilin Hu, Yu Dong, et al.. (2024). Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. Immunity. 57(3). 528–540.e6. 64 indexed citations breakdown →
11.
Liu, Kan, et al.. (2024). Therapeutic effect and mechanism of Yougui Wan in rats with intervertebral disk degeneration. Journal of Orthopaedic Surgery and Research. 19(1). 2 indexed citations
12.
Tang, Kai, Min Zhao, Yahong Wu, et al.. (2022). Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors. European Journal of Medicinal Chemistry. 230. 114106–114106. 10 indexed citations
13.
Huang, Rong, Tao Zheng, Yu Dong, et al.. (2022). Genome-wide placental DNA methylations in fetal overgrowth and associations with leptin, adiponectin and fetal growth factors. Clinical Epigenetics. 14(1). 192–192. 11 indexed citations
14.
Wang, Zhiwei, Ling Ran, Chunxia Chen, et al.. (2021). Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma. Vaccines. 9(10). 1118–1118. 2 indexed citations
15.
Dong, Yu, Yanfeng Gao, Yubing Li, et al.. (2021). Identification of CTL Epitopes on Efflux Pumps of the ATP-Binding Cassette and the Major Facilitator Superfamily of Mycobacterium tuberculosis. Journal of Immunology Research. 2021. 1–13. 4 indexed citations
16.
Han, Baohui, Tianqing Chu, Runbo Zhong, et al.. (2021). OA07.09 Sintilimab in Combination with Anlotinib as First-Line Therapy for Advanced NSCLC: Final Analysis of Primary Endpoints. Journal of Thoracic Oncology. 16(3). S119–S119.
17.
Lü, Jun, Weidong Zhang, Bin Yan, et al.. (2018). Tumor mutation index as a biomarker for responsive stratification on multi-targeted TKI anlotinib: An ALTER-0303 companion diagnostic study. Annals of Oncology. 29. ix113–ix113. 2 indexed citations
18.
Lin, Tao, Yun Zhao Chen, Yu Dong, et al.. (2016). Preoperative Body Mass Index, Blood Albumin and Triglycerides Predict Survival for Patients with Gastric Cancer. PLoS ONE. 11(6). e0157401–e0157401. 51 indexed citations
19.
20.
Zhang, Yanwei, Bo Jin, Minhua Shao, et al.. (2014). Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma. Tumor Biology. 35(5). 4921–4928. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lin Zhao Breakdown of academic impact, for papers by Yongfeng Ding Breakdown of academic impact, for papers by Ling Guo Breakdown of academic impact, for papers by Kazuhiko Yoshimatsu Breakdown of academic impact, for papers by Itaru Omoto Breakdown of academic impact, for papers by Shinobu Kunugi Breakdown of academic impact, for papers by Donglin Sun
Rankless by CCL
2026